Abstract 6404: NOTCH1 drives immunogenicity through STING and improves survival with immune checkpoint blockade in small cell lung cancer
Yoo Sun Kim(National Cancer Institute), Nitin Roper(Center for Cancer Research), Anagh Ray(National Cancer Institute), Robin Sebastian(National Institutes of Health), Christophe E. Redon(Center for Cancer Research), Priyanka Gopal(Northwestern University), Barzin Y. Nabet(Gene Therapy Laboratory), Yves Pommier(National Cancer Institute), Jane B. Trepel(National Institutes of Health), Mirit I. Aladjem(National Institutes of Health), Þorkell Andrésson(National Institutes of Health), David S. Shames(Gene Therapy Laboratory), Noémi Kedei(Center for Cancer Research), Nai-Yun Sun(National Cancer Institute), Moises J. Velez(University of Rochester Medical Center), N Sato(National Cancer Institute), Alberto Chiappori(Moffitt Cancer Center), Mohamed E. Abazeed(Northwestern University), Sudipto Das(National Cancer Institute), Shraddha Rastogi(National Cancer Institute), Haobin Chen(Washington University in St. Louis), Min-Jung Lee(National Cancer Institute), Hongliang Zhang(National Natural Science Foundation of China), Suresh Kumar(National Cancer Institute), Briana N. Cortez(National Cancer Institute), Alan E. Bers(National Cancer Institute), Sivasish Sindiri(National Institutes of Health)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k